This content is machine translated Mental Health with GLP-1 RAs Benefits of Semaglutide and Liraglutide GLP-1 receptor agonists are established treatments for type 2 diabetes and obesity. Depression and anxiety disorders are common among people with diabetes and obesity, and both conditions are associated with...…
View Post 12 min This content is machine translated The Brain and the Motivation to Eat Why is it so hard to lose weight? Obesity is the most common chronic disease in Western societies, with serious metabolic, cardiovascular, and psychosocial consequences. The therapeutic landscape has changed fundamentally: new-generation GLP-1 agonists achieve weight loss that,...… CME-Test
View Post 12 min This content is machine translated Global Recommendation, Swissmedic Approval, and SL Limitation WHO Guidelines on GLP-1 for Obesity With the guideline published on December 1, 2025, the World Health Organization has, for the first time, issued a globally applicable recommendation on the pharmacological management of obesity in adults....…
View Post 18 min This content is machine translated From Risk Identification to Anti-Inflammatory Intervention Inflammation as a Treatment Goal in Its Own Right For decades, cardiovascular prevention was essentially a story about cholesterol. Yet a significant proportion of patients experience adverse events despite optimally controlled lipid levels—a reflection of a residual risk that...… CME-Test
View Post 4 min This content is machine translated SwissDiab Study: New Analysis Published How are diabetes complications associated with quality of life? The Swiss Diabetes Registry (SwissDiab) is a multicenter, national observational study and patient registry that collects data on complications in adults with diabetes mellitus in Switzerland. A recent analysis published...…
View Post 13 min This content is machine translated Obesity Treatment Oral GLP-1 Therapies: ATTAIN-1 and OASIS-4—The Next Leap Forward Injectable GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide have redefined pharmacological obesity treatment and achieved weight loss in the range of 15 to 20% in clinical trials. Nevertheless,...…
View Post 12 min This content is machine translated SURPASS-CVOT Tirzepatide versus Dulaglutide in T2D with ASCVD GLP-1 receptor agonists have established themselves in recent years as a class of drugs with cardiovascular protective effects in type 2 diabetes. For dulaglutide, the 2019 REWIND study showed that...…
View Post 12 min This content is machine translated Cardiology and Nutrition Ultra-Processed Foods and Cardiovascular Risk—The New AHA Position Ultra-processed foods (UPFs ) account for a significant portion of energy intake in Western countries—in the United States, an estimated more than half. Given this ubiquity and a growing number...…
View Post 11 min This content is machine translated Cardiometabolism Retatrutid and the TRIUMPH Program: The Triple Agonist on the Horizon Incretin-based obesity therapy has advanced rapidly in just a few years: from GLP-1 receptor agonists (semaglutide) to the dual GIP/GLP-1 agonist tirzepatide and on to a triple agonist. Retatrutide (LY3437943)...…
View Post 12 min This content is machine translated Hepatology and Metabolism The Mediterranean Diet for MASLD/MASH—What the EASL-EASD-EASO Guidelines Specifically Recommend Since an international Delphi consensus in 2023, the condition formerly known as nonalcoholic fatty liver disease (NAFLD) has been called MASLD— “metabolic dysfunction-associated steatotic liver disease.” It is defined as...…
View Post 15 min This content is machine translated Obesity, Nutrition, and Mental Health Depression, Binge Eating, Internalized Stigma Cardiometabolic outcomes rightly dominate obesity care. However, the psychological dimension is by no means a footnote: depression, disordered eating, and an often-overlooked internalized weight stigma influence the burden of disease,...…
